Alps Group Inc Launches Pharmaco-Interaction (PCI) Unit via MyGenome, Debuting with CYP450 Drug Interaction Testing
Alps Group (NASDAQ: ALPS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Care Providers industry, part of the Healthcare sector.
The shares were at 1.150 USD on 20 November 2026, up 35.3% over 52 weeks. Its 52-week range is 0.2290 USD to 2.020 USD: the price is 43.1% below the high and 402.2% above the low.
Its market capitalisation is 36.43M USD.
Alps Group reports return on equity of 68.7%.
Its Piotroski F-score is 5 out of 9, an average reading of its financial health.
No upcoming events tracked.